#CurativeBiotech does our part in the fight against #ChildhoodCancer. Read our CEO's blog post curativebiotech.com/how-do-you-mea…. Richard talks about developing our first-in-class treatment for #BrainTumor & how our antibody delivers an anti-cancer "warhead" to target #Glioblastoma. $CTYX

World renown scientist Dimitrov joins #CurativeBiotech Scientific and Clinical Advisory Board and will guide our development of novel treatment for #Glioblastoma. Another win for #ChildhoodCancer, #BrainTumor, & #RareDisease. $CTYX backend.otcmarkets.com/otcapi/company…

#CurativeBiotech has been notified of the symbol change on the FINRA Daily List 4/28/2021.   This corporate action will take effect at the open of business on 4/29/2021. The new symbol will be $CUBT

#CurativeBiotech is pleased to begin trading under our new symbol $CUBT today. We thank our followers for their likes, retweets, and most of all, patience. Here's our press release that covers the noteworthy past month. prn.to/2QFojrp

Matters of Vision! 2021 Virtual Patient Seminars May 19th- "Genetics & AMD " Steven Ferrucci, OD, FAAO The program begins @ 12:00 pm EST and lasts 1 ½ hrs. with interactive Q & A. Please use this link to register: macularhope.org/gamd/ #ForeseeHome #Steven Ferrucci, OD, FAAO

#CurativeBiotech brings hope for #RareDiseases “from bench to bedside” and CEO Richard Garr reflects on how complex and connected every step of the process is. lnkd.in/gKB7Rzy $CUBT

#CurativeBiotech has filed our first quarter results and Chairman Paul Michaels shares his thoughts in a Letter to Shareholders lnkd.in/gqykVDn $CUBT

#CurativeBiotech is pleased to welcome Marc Drimer to the Board and Audit Committee $CUBT globenewswire.com/news-release/2…

#Curative Welcomes Dr. Nicholas Boulis, MD/PhD to our Scientific and Clinical Advisory Board. Clinical Program for CD56 Monoclonal Antibody Drug Conjugate for Treatment of #Glioblastoma to Benefit from Expertise in #Neurobiology lnkd.in/gWCYCKaG

Curative Biotech we are developing our late stage #rabies therapeutic mostly for outside of the U.S. but we are not immune here either. foxnews.com/health/illinoi…

#CurativeBiotech plans to develop a novel #COVID-19 vaccine targeted for highly vulnerable #Immunocompromised patients. #KidneyFailure #KidneyTransplant #Dialysis prnewswire.com/news-releases/…

#CurativeBiotech Welcomes Dr. Catherine Sohn as Special Advisor to Board and CEO! She will oversee development of next-gen #COVID19 vaccine to treat #kidneyfailure patients, late-stage #rabies therapeutic and age-related macular degeneration curativebiotech.com/curative-biote…

#CurativeBiotech Announces Ocular Tolerance Evaluation of Metformin Eye Drop Formulations for Treatment of Macular Degeneration Company’s First In-license Pipeline Product to Enter Pre-clinical Studies curativebiotech.com/curative-biote…

Curative Announces CRADA with NEI for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in AMD. Principal Investigator Emily Chew MD curativebiotech.com/curative-biote…

#CurativeBio Announces GLP Toxicology Studies with Metformin Eye Drop Formulations for Treatment of #AMD. Requirement for FDA (IND) filing. NEI to Collaborate. curativebiotech.com/curative-biote…

#CurativeBiotech Appoints Cary Sucoff to Board of Directors curativebiotech.com/curative-biote…

#CurativeBiotech adds biotech veteran Lawrence S. Zaslow to Board of Directors curativebiotech.com/curative-biote…

#CurativeBiotech Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study globenewswire.com/news-release/2…